MedTrace Logo

Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area

NCT01426373 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2016-01-14

Study results available
· View outcomes & findings →

Summary

To evaluate the safety of deoxycholic acid subcutaneous injections in the submental area (below the chin).

Conditions

  • Moderate or Severe Submental Fullness

Interventions

DRUG

Deoxycholic acid injection

Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.

Sponsors & Collaborators

  • Kythera Biopharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Frederick Beddingfield, III, M.D., PhD · Kythera Biopharmaceuticals, Inc

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01426373 on ClinicalTrials.gov